Works matching Abbott Pharmaceuticals Corp.


Results: 42
    1
    2
    3
    4

    131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial.

    Published in:
    Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-131-LB
    By:
    • LIAO, JINLAN;
    • KANG, AMY;
    • XIA, CHAO;
    • ARNOTT, CLARE;
    • TANNA, GIAN LUCA DI;
    • KRISHNAN, ARUN V.;
    • POLLOCK, CAROL A.;
    • AGARWAL, RAJIV;
    • BAKRIS, GEORGE;
    • HEERSPINK, HIDDO L.;
    • LEVIN, ADEERA;
    • DE ZEEUW, DICK;
    • NEAL, BRUCE;
    • ZHANG, HONG;
    • WHEELER, DAVID C.;
    • ZINMAN, BERNARD;
    • MAHAFFEY, KENNETH W.;
    • PERKOVIC, VLADO;
    • JARDINE, MEG J.;
    • SMYTH, BRENDAN
    Publication type:
    Article
    5

    129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial.

    Published in:
    Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-129-LB
    By:
    • YI, TAE WON;
    • SMYTH, BRENDAN;
    • KANG, AMY;
    • CARDOZA, KATHRYN;
    • TANNA, GIAN LUCA DI;
    • ARNOTT, CLARE;
    • POLLOCK, CAROL A.;
    • AGARWAL, RAJIV;
    • BAKRIS, GEORGE;
    • CANNON, CHRISTOPHER P.;
    • DE ZEEUW, DICK;
    • HEERSPINK, HIDDO L.;
    • LEVIN, ADEERA;
    • NEAL, BRUCE;
    • WHEELER, DAVID C.;
    • ZHANG, HONG;
    • ZINMAN, BERNARD;
    • MAHAFFEY, KENNETH W.;
    • PERKOVIC, VLADO;
    • JARDINE, MEG J.
    Publication type:
    Article
    6
    7
    8

    747-P: Improved Treatment Perceptions with IGlarLixi vs. Premix Insulin in Type 2 Diabetes (T2D) Uncontrolled on Basal Insulin (BI) + Oral Antihyperglycemic Drugs (OADs): Patient-Reported Outcomes (PROs) of the SoliMix Trial.

    Published in:
    Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-747-P
    By:
    • POLONSKY, WILLIAM H.;
    • MCCRIMMON, RORY J.;
    • WHITMIRE, KATHERINE H.;
    • GIORGINO, FRANCESCO;
    • CHEN, JUNG-FU;
    • NICHOLLS, CHARLIE;
    • LEW, ELISHEVA;
    • ALVAREZ, AGUSTINA;
    • COUDERT, MATHIEU;
    • ROSENSTOCK, JULIO
    Publication type:
    Article
    9
    10
    11
    12
    13

    144-LB: Medicaid Expansion and Utilization of Antihyperglycemic Therapies.

    Published in:
    Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-144-LB
    By:
    • SUMARSONO, ANDREW;
    • BUCKLEY, LEO;
    • MACHADO, SARA R.;
    • WADHERA, RISHI K.;
    • WARRAICH, HAIDER;
    • DESAI, RISHI J.;
    • EVERETT, BRENDAN M.;
    • MCGUIRE, DARREN K.;
    • FONAROW, GREGG C.;
    • BUTLER, JAVED;
    • PANDEY, AMBARISH;
    • VADUGANATHAN, MUTHIAH
    Publication type:
    Article
    14
    15
    16
    17
    18
    19
    20
    21
    22

    4-LB: Substantial Cardiovascular Benefit from Icosapent Ethyl in Patients with Diabetes: REDUCE-IT DIABETES.

    Published in:
    Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-4-LB
    By:
    • BHATT, DEEPAK L.;
    • BRINTON, ELIOT A.;
    • MILLER, MICHAEL;
    • STEG, PHILIPPE G.;
    • JACOBSON, TERRY A.;
    • KETCHUM, STEVEN B.;
    • DOYLE, RALPH T.;
    • JULIANO, REBECCA A.;
    • JIAO, LIXIA;
    • GRANOWITZ, CRAIG;
    • GANDA, OM;
    • WELTY, FRANCINE K.;
    • BUSCH, ROBERT S.;
    • GOLDBERG, ANNE C.;
    • HERRINGTON, DAVID M.;
    • BUDOFF, MATTHEW;
    • TARDIF, JEAN-CLAUDE;
    • BALLANTYNE, CHRISTIE M.
    Publication type:
    Article
    23
    24
    25
    26
    27
    28
    29
    30
    31

    803-P: Modifiable Diabetes-Specific Factors and Glycemic Control in Economically Vulnerable and Racial/Ethnic Minority Young Adults with Type 1 Diabetes.

    Published in:
    Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-803-P
    By:
    • AGARWAL, SHIVANI;
    • KANAPKA, LAUREN;
    • RAYMOND, JENNIFER;
    • WALKER, ASHBY F.;
    • GONZALEZ, ANDREA GERARD;
    • KRUGER, DAVIDA F.;
    • REDONDO, MARIA JOSE;
    • RICKELS, MICHAEL R.;
    • SHAH, VIRAL N.;
    • BUTLER, ASHLEY;
    • MILLER, VICTORIA;
    • VERDEJO, ALANDRA;
    • GAL, ROBIN L.;
    • WILLI, STEVEN M.;
    • LONG, JUDITH A.
    Publication type:
    Article
    32
    33
    34
    35

    343-LB: The Type 2 Diabetes-Associated Lipid Binding Protein STARD10 Controls Insulin Secretory Granule Biogenesis.

    Published in:
    Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-343-LB
    By:
    • CARRAT, GAELLE;
    • HAYTHORNE, ELIZABETH;
    • HAATAJA, LEENA;
    • ARVAN, PETER;
    • TOMAS, ALEJANDRA;
    • PIUNTI, ALEXANDRA;
    • PULLEN, TIMOTHY J.;
    • GEORGIADOU, ELENI;
    • STYLIANIDES, THEODOROS;
    • SALEM, VICTORIA;
    • DISTASO, WALTER;
    • CAKEBREAD, ANDREW;
    • HODSON, DAVID;
    • FUNG, ANNIE C.;
    • SESSIONS, RICHARD B.;
    • ALPY, FABIEN;
    • KONG, ALICE P.;
    • LECLERC, ISABELLE;
    • RUTTER, GUY A.
    Publication type:
    Article
    36
    37
    38
    39
    40
    41

    Sertindole (Serlect)...

    Published in:
    Brown University Psychopharmacology Update, 1998, v. 9, n. 4, p. 5
    Publication type:
    Article
    42

    In brief.

    Published in:
    Nature, 2007, v. 446, n. 7134, p. 363, doi. 10.1038/446363a
    Publication type:
    Article